It is widely acknowledged that deregulated NF-κB signaling may contribute to acute neurodegenerative conditions, such as cerebral ischemia and traumatic brain injury (Harari and Liao, 2010) as well as chronic neurodegenerative disorders, such as Alzheimer's disease (Jones and Kounatidis, 2017), Parkinson's disease (Flood et al., 2011), Huntington's disease (Bečanović et al., 2015), and ALS (Sako et al., 2012). This evidence concerns the gene NFKB1 and early-onset autosomal dominant Alzheimer disease.